Mizuho Securities Downgrades Eagle Pharmaceuticals (EGRX) to Neutral; Stock to Plateau Post-Analyst Day

November 16, 2016 6:28 AM EST
Get Alerts EGRX Hot Sheet
Price: $75.20 +1.14%

Rating Summary:
    4 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade EGRX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Mizuho Securities downgraded Eagle Pharmaceuticals (NASDAQ: EGRX) from Buy to Neutral while maintaining a $78 price target.

Analyst Irina Koffler commented, "We expect the stock to plateau after the Analyst Day due to lighter catalyst flow, weaker Treanda/Bendeka revenues reported by partner Teva, and fully loaded pipeline valuation."

For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.

Shares of Eagle Pharmaceuticals closed at $81.98 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Downgrades

Related Entities

Irina Koffler

Add Your Comment